Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® (AP) platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.
Intec’s strategy is to leverage its proprietary delivery technology to improve the properties of known/approved compounds, with plans to partner these for full development and commercialization. Intec also plans to work in collaboration with biotechnology and pharmaceutical companies to develop novel delivery systems for their proprietary drugs, including existing compounds undergoing lifecycle management.
The Company’s product pipeline includes four candidates in clinical development:
- Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which recently completed a Phase 3 trial for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and
- AP-cannabinoids, early stage development of a system to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various indications including cancer pain and opioid-sparing pain management.